BCL2 and hepatocellular carcinoma: Moreover, the combination of adenine and cisplatin treatment contributed to the lower expression level of Bcl-2 and higher levels of PUMA, cleaved caspase-3, and PARP in HCC cells compared to treatment with adenine or cisplatin alone (p < 0.05).